M III (M-4) MOUSE HYBRIDOMA (HB-8438)

Designation / Description M III (M-4) MOUSE HYBRIDOMA
U.S. Patent Number
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Comments
Animals were immunized with the human cutaneous melanoma cells.
The antibody reacts with a cell surface antigen on human melanoma cells (gp110).
The antibody reacts with the M-4 antigen system.
Shipped frozen
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Basic Documentation
Restrictions

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

References

Houghton AN, et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156: 1755-1766, 1982. PubMed: 7175440

Real FX, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 45: 4401-4411, 1985. PubMed: 4028024

Cairncross JG, et al. Monoclonal antibodies against melanocytes. US Patent 4,806,628 dated Feb 21 1989

Oettgen HF, et al. Monoclonal antibodies to cell surface antigens of human malignant melanoma. US Patent 4,808,704 dated Feb 28 1989